In clinical studies, high expression of SLC7A11 in patients with pulmonary cancer, pancreatic cancer, liver carcinoma, thyroid carcinoma, melanoma, or glioma was associated with a poor prognosis [122,123,124,125,126,127]. Here, SLC7A11 is linked to central nervous system cancer.